Literature DB >> 28295453

Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models.

Anna D Kosinska1,2, Leila Pishraft-Sabet1, Weimin Wu1, Zhong Fang2,3, Marzena Lenart4, Jieliang Chen3, Kirsten K Dietze1, Cong Wang2, Thekla Kemper1, Yong Lin1, Shiou-Hwei Yeh5,6, Jia Liu1, Ulf Dittmer1, Zhenghong Yuan2,3, Michael Roggendorf1, Mengji Lu1.   

Abstract

Hepatitis B virus (HBV) infection shows significant gender-related differences in pathogenesis, disease progression, and development of hepatocellular carcinoma. The gender-associated differences in HBV replication and viral protein levels may be associated with distinct HBV-specific immune responses in the host. In the present study, we examined the impact of gender on HBV-specific immune responses in two different mouse models representing transient and persistent hepadnaviral infection; hydrodynamic injection with the HBV genome mimicked acute HBV infection, whereas the efficacy of therapeutic vaccination was studied in the woodchuck hepatitis virus transgenic mouse model. Consistent with previous reports, significantly higher HBV DNA and protein levels were detected in male compared to female mice. Although hydrodynamic injection with the HBV genome resulted in similar numbers of intrahepatic HBV-specific cluster of differentiation 8-positive (CD8+ ) T cells, their functionality was significantly reduced in males and correlated with higher numbers of intrahepatic regulatory T cells (Tregs). Similar effects were observed in woodchuck hepatitis virus transgenic mice immunized with a DNA prime-recombinant adenovirus boost vaccination protocol. Male mice showed functionally suppressed woodchuck hepatitis virus-specific CD8+ T-cell responses in the liver and significantly higher numbers of intrahepatic Tregs compared to females. Blockade of Treg responses in male mice led to augmented effector functions of specific CD8+ T cells and subsequently improved virus control in both models of transient and persistent hepadnaviral infection.
CONCLUSION: The functionality of virus-specific CD8+ T cells in male mice was suppressed by intrahepatic Tregs and inversely correlated with levels of hepadnaviral DNA and viral protein; the induction of intrahepatic Tregs by viral replication and/or protein levels may explain the gender-related differences in the outcomes of HBV infection and limit the success of immunotherapeutic strategies in male patients. (Hepatology 2017;66:69-83).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28295453     DOI: 10.1002/hep.29155

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.

Authors:  Di Wu; Peng Wang; Meifang Han; Yongping Chen; Xinyue Chen; Qi Xia; Weiming Yan; Xiaoyang Wan; Chuanlong Zhu; Qing Xie; Jiaji Jiang; Lai Wei; Deming Tan; Xiaoguang Dou; Yanyan Yu; Jinlin Hou; Xiaoping Luo; Qin Ning
Journal:  Hepatol Int       Date:  2019-06-06       Impact factor: 6.047

2.  Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.

Authors:  Keigo Kawashima; Masanori Isogawa; Susumu Hamada-Tsutsumi; Ian Baudi; Satoru Saito; Atsushi Nakajima; Yasuhito Tanaka
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

3.  The IL-1R/TLR signaling pathway is essential for efficient CD8+ T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model.

Authors:  Zhiyong Ma; Jia Liu; Weimin Wu; Ejuan Zhang; Xiaoyong Zhang; Qian Li; Gennadiy Zelinskyy; Jan Buer; Ulf Dittmer; Carsten J Kirschning; Mengji Lu
Journal:  Cell Mol Immunol       Date:  2017-07-31       Impact factor: 11.530

Review 4.  Hepatitis B virus infection: Defective surface antigen expression and pathogenesis.

Authors:  Chun-Chen Wu; Ying-Shan Chen; Liang Cao; Xin-Wen Chen; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2018-08-21       Impact factor: 5.742

5.  Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis.

Authors:  Qian Li; Yan Yan; Jia Liu; Xuan Huang; Xiaoyong Zhang; Carsten Kirschning; Haifeng C Xu; Philipp A Lang; Ulf Dittmer; Ejuan Zhang; Mengji Lu
Journal:  Front Immunol       Date:  2019-09-12       Impact factor: 7.561

Review 6.  Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response.

Authors:  Zhiyong Ma; Ejuan Zhang; Shicheng Gao; Yong Xiong; Mengji Lu
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

7.  Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment.

Authors:  Qin Wang; Wen Pan; Yanan Liu; Jinzhuo Luo; Dan Zhu; Yinping Lu; Xuemei Feng; Xuecheng Yang; Ulf Dittmer; Mengji Lu; Dongliang Yang; Jia Liu
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

8.  Pre-Activation of Toll-Like Receptor 2 Enhances CD8+ T-Cell Responses and Accelerates Hepatitis B Virus Clearance in the Mouse Models.

Authors:  Yong Lin; Xuan Huang; Jun Wu; Jia Liu; Mingfa Chen; Zhiyong Ma; Ejuan Zhang; Yan Liu; Shunmei Huang; Qian Li; Xiaoyong Zhang; Jinlin Hou; Dongliang Yang; Mengji Lu; Yang Xu
Journal:  Front Immunol       Date:  2018-06-29       Impact factor: 7.561

Review 9.  Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?

Authors:  Anna Ruggieri; Maria Cristina Gagliardi; Simona Anticoli
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

Review 10.  Sex Hormone-Dependent Physiology and Diseases of Liver.

Authors:  Paulina Kur; Agnieszka Kolasa-Wołosiuk; Kamila Misiakiewicz-Has; Barbara Wiszniewska
Journal:  Int J Environ Res Public Health       Date:  2020-04-11       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.